Morgan Stanley analyst Connor Lynagh maintains Cactus (NYSE:WHD) with a Equal-Weight and lowers the price target from $60 to $50.
Candel Therapeutics Announces Restructuring To Prioritize Resources On Key Value Drivers For Expanded Development Of CAN-3110, The enLIGHTEN Discovery Platform, And Key Clinical Readouts For CAN-2409; Decreases Workforce By ~50%
Decreases workforce by approximately 50% and reduces commercial manufacturing expenses to prioritize spend towards topline clinical data readouts for CAN-2409 in non-small cell lung cancer, pancreatic cancer, and
